BASEL, SWITZERLAND--(MARKET WIRE)--Sep 18, 2007 -- Basilea Pharmaceutica Ltd. (Swiss:BSLN.SW - News) today announced that previously unpublished data on ceftobiprole were presented in 23 posters at the Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chicago. The detailed clinical and microbiological results of the phase III program demonstrate ceftobiprole’s potential breadth of activity in complicated skin infections involving Gram-positive and Gram-negative pathogens.
